JP2005531622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005531622A5 JP2005531622A5 JP2004516730A JP2004516730A JP2005531622A5 JP 2005531622 A5 JP2005531622 A5 JP 2005531622A5 JP 2004516730 A JP2004516730 A JP 2004516730A JP 2004516730 A JP2004516730 A JP 2004516730A JP 2005531622 A5 JP2005531622 A5 JP 2005531622A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- components
- administration
- administered
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229960004964 temozolomide Drugs 0.000 description 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39258902P | 2002-06-28 | 2002-06-28 | |
| PCT/EP2003/006848 WO2004002485A1 (en) | 2002-06-28 | 2003-06-27 | Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005531622A JP2005531622A (ja) | 2005-10-20 |
| JP2005531622A5 true JP2005531622A5 (enExample) | 2006-08-17 |
Family
ID=30000898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004516730A Pending JP2005531622A (ja) | 2002-06-28 | 2003-06-27 | 血管沈静化合物とアルキル化剤を含む腫瘍処置用の組合せ剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7754716B2 (enExample) |
| EP (1) | EP1545527A1 (enExample) |
| JP (1) | JP2005531622A (enExample) |
| CN (1) | CN100355423C (enExample) |
| AU (1) | AU2003249895A1 (enExample) |
| BR (1) | BR0312283A (enExample) |
| CA (1) | CA2490130A1 (enExample) |
| WO (1) | WO2004002485A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1922311A2 (en) | 2005-09-09 | 2008-05-21 | Brystol-Myers Squibb Company | Acyclic ikur inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5939098A (en) * | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| EP1339458B1 (en) * | 2000-11-22 | 2007-08-15 | Novartis AG | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| NZ527947A (en) | 2001-02-02 | 2005-10-28 | Schering Corp | 3,4-di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists |
| GB0111078D0 (en) * | 2001-05-04 | 2001-06-27 | Novartis Ag | Organic compounds |
| JP2005505595A (ja) | 2001-10-12 | 2005-02-24 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物 |
-
2003
- 2003-06-27 JP JP2004516730A patent/JP2005531622A/ja active Pending
- 2003-06-27 CA CA002490130A patent/CA2490130A1/en not_active Abandoned
- 2003-06-27 CN CNB038149222A patent/CN100355423C/zh not_active Expired - Fee Related
- 2003-06-27 US US10/518,989 patent/US7754716B2/en not_active Expired - Fee Related
- 2003-06-27 WO PCT/EP2003/006848 patent/WO2004002485A1/en not_active Ceased
- 2003-06-27 BR BR0312283-2A patent/BR0312283A/pt not_active IP Right Cessation
- 2003-06-27 AU AU2003249895A patent/AU2003249895A1/en not_active Abandoned
- 2003-06-27 EP EP03761547A patent/EP1545527A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016256471B2 (en) | Methods of treating cancer | |
| CN115297862A (zh) | 包含达拉菲尼、erk抑制剂和shp2抑制剂的三重药物组合 | |
| JP2012500180A5 (enExample) | ||
| JP6570512B2 (ja) | 新規なＳｔａｔ３阻害剤 | |
| JP2022531906A (ja) | 関節炎性疾患の組み合わせ療法 | |
| TW202302095A (zh) | 使用ｂｅｔ抑制劑治療骨髓纖維化 | |
| US20090312290A1 (en) | Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia | |
| KR20240104138A (ko) | 니로가세스타트를 사용한 조성물 및 치료 | |
| EP3503925A1 (en) | Compositions comprising pikfyve inhibitors and methods related to inhibition of rank signaling | |
| TW201006823A (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis | |
| NZ550174A (en) | Combinations comprising a vasculostatic compound such as vatalanib and epothilones, and pharmaceutical uses thereof | |
| TWI776451B (zh) | Bcl-2/bcl-xl抑制劑之組合及相關用途 | |
| RU2322238C2 (ru) | Лечение ревматоидного артрита | |
| WO2022218958A1 (en) | Combination comprising everolimus and amcenestrant | |
| WO2019042226A1 (zh) | 用于肿瘤治疗或预防的药物组合物、方法及其用途 | |
| TW202203928A (zh) | 硫代胺基甲酸酯衍生物ａ２ａ抑制劑的施用方法及調配物 | |
| JP2005531622A5 (enExample) | ||
| WO2023204259A1 (ja) | がんの治療又は予防用医薬 | |
| WO2019004465A1 (ja) | ペマフィブラートを含有する医薬 | |
| CN100355423C (zh) | 用于治疗肿瘤的包含血管抑制化合物和烷化剂的组合 | |
| EP1485090B1 (en) | Combinations comprising an epothilone derivative and an imidazotetrazinone | |
| US20030139430A1 (en) | Use of organic compounds | |
| WO2024010030A1 (ja) | 血中マイオスタチン低下剤 | |
| US20230210792A1 (en) | Use of a combination of colchicine and a cxcr-2 inhibitors for the treatment or prevention of familial mediterranean fever (fmf) and flare-ups thereof | |
| JP2024531653A (ja) | 固形腫瘍の処置のための経口投与パクリタキセル、Ｐ－ｇｐ阻害剤、およびチェックポイント阻害剤の治療的組み合わせ |